| Bioactivity | SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against apanel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases[1]. |
| Target | IC50：0.061 μM (Nsp14 MTase) |
| Invitro | SARS-CoV-2 nsp14-IN-1 (Compound 3) displays an excellent selectivity profile for Nsp14 MTase With an IC50 value of 0.061 μM.SARS-CoV-2 nsp14-IN-1 (Compound 3) shows low passive diffusion rates in PAMPA.SARS-CoV-2 nsp14-IN-1 (Compound 3) does not suffer major metabolic liabilities in human plasma and liver S9 fractions[1]. |
| Name | SARS-CoV-2 nsp14-IN-1 |
| CAS | 2816165-02-1 |
| Formula | C20H20N6O5S |
| Molar Mass | 456.48 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Eunkyung Jung, et al. Bisubstate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase. ACS Med. Chem. Lett. July 22, 2022. |
SARS-CoV-2 nsp14-IN-1
CAS: 2816165-02-1 F: C20H20N6O5S W: 456.48
SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC50 value of
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.